Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: A meta-analysis

Current Diabetes Reviews

Volumn 3, Issue 2, 2007, Pages 127-140

  Norris, Susan L ^a,b   Carson, Susan ^a   Roberts, Carol ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Meta analyisis; Oral hypoglycemic agents; Systematic review; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ANEMIA; ARTHRALGIA; BACKACHE; BODY WEIGHT; BRONCHITIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; COUGHING; DATA BASE; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FLATULENCE; FLU LIKE SYNDROME; FOLLOW UP; HEART BUNDLE BRANCH BLOCK; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INJURY; LEG PAIN; LIVER FUNCTION TEST; META ANALYSIS; METABOLIC SYNDROME X; MONOTHERAPY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL DISORDER; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; PREDIABETIC STATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 34248647627     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339907780598216     Document Type: Review

References (93)

1. FDA: Rezulin to be withdrawn from the market. In HHS News, U.S. Department of Health and Human Services, 2000.
2. PDR: Pioglitazone. In Physicians' Desk Reference, 60th edition, Montvale, NJ, 2006; 3224-28.
3. PDR: Rosiglitazone. In Physicians' Desk Reference, 60th edition, Montvale, NJ, 2006; 1348-53.
4. Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-37.
5. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-63.
6. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
7. Harris RP, Helfand M, Woolf S. Current methods of the third US Preventative Services Task Force. Am J Prev Med 2001; 20: 21-35.
8. Anonymous: Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report Number 4 (2nd Edition), York, UK. NHS Centre for Reviews and Dissemination 2001; 4.
9. Higgins J, Green S, Editors: Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (updated May 2005). 2005.
10. DerSimonian R, Laird N. Meta-analyses in clinical trials. Control Clin Trials 1954; 7: 177-88.
11. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
12. Glenny AM, Altman DH, Song F, et al. Indirect comparisons of competing interventions Available at: http://wwwncchtaorg/exec-summ/ summ926htm Health Technology Assessment NHS R&D HTA Programme, July 2005.
13. Thorton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000; 53: 207-16.
14. Tang J. Liu J. Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol 2000; 53: 477-84.
15. Terrin N, Schmid C, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 2005; 58: 894-901.
16. Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-54.
17. Derosa G, Cicero AFG, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005; 69: 5-13.
18. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-54.
19. Kahn MA, St. Peter J, Xue JL. A prospective, randomized comparison of the metabolic erffects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previoulsy treated with troglitazone. Diabetes Care 2002; 25: 708-11.
20. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-11.
21. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes, related to lipid storage in vivo. Diabetes Care 2004; 27: 1660-7.
22. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, Group QUARTETS: A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005; 22: 399-405.
23. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial In Macrovascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
24. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 1074-95.
25. Kipnes MS, Krosnick, A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111: 10-7.
26. Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005; 27: 554-67.
27. McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF. Effect of a peroxisome proliferator-activated receptor-(gamma) agonist on myocardial blood flow in type 2 diabetes. Diabetes Care 2005; 28: 1145-50.
28. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-9.
29. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 4312-9.
30. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517-23.
31. Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol 2004; 29: 11-7.
32. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-23.
33. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in pati,ents receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-7.
34. Saad MF, Greco S, Osei K, et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 2004; 27: 1324-9.
35. Scherbaum WA, Goke B, German Pioglitazone Study G. Metabolic efficacy and safety of once-daily pioglitszone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002; 34: 589-95.
36. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005; 54: 24-32.
37. Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003; 146: E5.
38. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004; 21: 568-76.
39. Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther 2003; 25: 2754-64.
40. Barnett AH, Grant PJ, Hitman GA, et al. Rosiglitazone in type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diabet Med 2003; 20: 387-93.
41. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-702.
42. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127-34.
43. Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002; 51: 3479-85.
44. Honisett SY, Stojanovska L, Sudhir K, Kingwell BA, Dawood T, Komesaroff PA. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care 2003; 26: 3194-5.
45. Iozzo P, Hallsten K, Oikonen V, et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose up-take and their relation to visceral fat in type 2 diabetes. Diabetes Care 2003; 26: 2069-74.
46. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-70.
47. Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract 2005; 67: 43-52.
48. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-8.
49. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 2001; 44: 2210-9.
50. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004; 27: 1349-57.
51. Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabet Med 2000; 17: 287-94.
52. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999; 1: 165-72.
53. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-15.
54. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278-84.
55. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-32.
56. Reynolds LR, Konz EC, Frederich RC, Anderson JW. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 270-5.
57. Tan GD, Fielding BA, Currie JM, et al. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 2005; 48: 83-95.
58. van Wijk JP, de Koning EJ, Castro Cabezas M, Rabelink TJ. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 2005; 28: 844-9.
59. Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003; 52: 283-90.
60. Wang G, Wei J, Guan Y, Jin N, Mao J, Wang X. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 2005; 54: 590-7.
61. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000; 17: 40-7.
62. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-80.
63. Zhu XX, Pan CY, Li. GW, et al. Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther 2003; 5: 33-42.
64. Choi D, Kim S-K, Choi S-H, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-60.
65. Kreider M, Heise M. Rosiglitazone in the management of older patients with type 2 diabetes mellitus. Int J Clin Pract 2002; 56: 538-41.
66. Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Drug Aging 2004; 21: 259-71.
67. King AB, Armstrong DU, Chinnapongse S. Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes. Diabetes Care 2003; 26: 245-6.
68. Vongthavaravat V, Wajchenberg BL, Waitman JN, et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin 2002; 18: 456-61.
69. Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003; 23: 861-5.
70. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004; 93: 362-5.
71. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004; 6: 280-5.
72. Hung YJ, Hsieh CH, Pei D, et al. Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance. Clin Endocrinol 2005; 62: 85-91.
73. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-96.
74. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26: 2983-9.
75. Frenchman IB. Treatment and treatment-related adverse events of type 2 diabetes mellitus in residents of long-term care facilities: A retrospective study. Curr Ther Res Clin Exp 2003; 64: 1-9.
76. Gegick CG, Altheimer MD. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. Curr Med Res Opin 2004; 20: 919-30.
77. Harmel AP. Treating diabetes: Cardiovascular benefits of antidiabetes drugs. Am J Manag Care 2002; 8: S219-S28.
78. Hussein Z, Wentworth JM, Nankervis AJ, Proietto J, Colman PG. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust 2004; 181: 536-9.
79. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000; 23: 557.
80. King KA, Levi VE. Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione. Am J Health Syst Pharm 2004; 61: 390-3.
81. LaCivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002; 18: 363-70.
82. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-21.
83. Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther 2003; 25 (Suppl B): B64-80.
84. Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 2005; 7: 161-9.
85. Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003; 41: 1394-8.
86. Boucher M, McAuley L, Brown A, Keely E, Skidmore B. Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents. Ottawa Canadian Coordinating Office for Health Technology Assessment Technology overview no 9, 20.
87. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164: 2097-104.
88. Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess 2004; 8: iii.
89. Moher D, Fortin P, Jadad A, et al. Completeness of reporting trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 1996; 347(8998): 363-6.
90. Moher D, Pham B, Klassen T, et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol 2000; 53(9): 964-72.
91. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999; 319: 670-74.
92. Chan A, Hrobjartsson A, Haahr M, Gotzsche P, Altman D. Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to publish articles. JAMA 2004; 291: 2457-65.
93. Glenny A, Altman D, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess (Winchester, England) 2605; 9 (26):1-134.